Preclinical Development of Magnetic Nanoparticles for Hyperthermia Treatment of Pancreatic Cancer.

Autor:	Díaz-Riascos ZV; Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT), Vall d'Hebron Institute of Research (VHIR), 08035 Barcelona, Spain.; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 08035 Barcelona, Spain.; Functional Validation & Preclinical Research (FVPR), Unit20 ICTS Nanbiosis, Vall d'Hebron Institute of Research (VHIR), 08035 Barcelona, Spain., Llaguno-Munive M; Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT), Vall d'Hebron Institute of Research (VHIR), 08035 Barcelona, Spain., Lafuente-Gómez N; IMDEA Nanociencia, Unidad Asociada al Centro Nacional de Biotecnología (CSIC) 28049 Madrid, Spain., Luengo Y; IMDEA Nanociencia, Unidad Asociada al Centro Nacional de Biotecnología (CSIC) 28049 Madrid, Spain., Holmes S; Nanomedicine and Molecular Imaging group, Trinity Translational Medicine Institute (TTMI), Trinity College Dublin (TCD), Dublin 8 Dublin, Ireland., Volatron J; Laboratoire Matière et Systèmes Complexes (MSC), UMR 7057 CNRS, Université Paris Diderot, Paris 75205, cedex, France., Ibarrola O; BioKeralty Research Institute AIE, 01510 Miñano, Spain., Mancilla S; Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT), Vall d'Hebron Institute of Research (VHIR), 08035 Barcelona, Spain.; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 08035 Barcelona, Spain.; Functional Validation & Preclinical Research (FVPR), Unit20 ICTS Nanbiosis, Vall d'Hebron Institute of Research (VHIR), 08035 Barcelona, Spain., Sarno F; Grupo de Oncología Traslacional, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain., Aguirre JJ; BioKeralty Research Institute AIE, 01510 Miñano, Spain., Razafindrakoto S; Laboratoire Matière et Systèmes Complexes (MSC), UMR 7057 CNRS, Université Paris Diderot, Paris 75205, cedex, France., Southern P; Resonant Circuits Limited, London W1S 4BS, U.K., Terán FJ; IMDEA Nanociencia, Unidad Asociada al Centro Nacional de Biotecnología (CSIC) 28049 Madrid, Spain.; Unidad Asociada de Nanobiotecnología (CNB-CSIC e IMDEA Nanociencia), 28049 Madrid, Spain.; Unidad de Nanomateriales Avanzados, IMDEA Nanociencia (Unidad de I+D+I Asociada al Instituto de Ciencia de Materiales de Madrid, CSIC), 28049 Madrid, Spain., Keogh A; Department of Histopathology, St. James's Hospital and Trinity College Dublin, Cancer Molecular Diagnostics, Dublin 8 Dublin, Ireland., Salas G; IMDEA Nanociencia, Unidad Asociada al Centro Nacional de Biotecnología (CSIC) 28049 Madrid, Spain.; Unidad Asociada de Nanobiotecnología (CNB-CSIC e IMDEA Nanociencia), 28049 Madrid, Spain.; Unidad de Nanomateriales Avanzados, IMDEA Nanociencia (Unidad de I+D+I Asociada al Instituto de Ciencia de Materiales de Madrid, CSIC), 28049 Madrid, Spain., Prina-Mello A; Nanomedicine and Molecular Imaging group, Trinity Translational Medicine Institute (TTMI), Trinity College Dublin (TCD), Dublin 8 Dublin, Ireland.; Trinity St. James's Cancer Institute, School of Medicine (TCD) and St. James's Hospital, Dublin 8 Dublin, Ireland.; Laboratory for Biological Characterisation of Advanced Materials (LBCAM), TTMI, School of Medicine, Trinity College Dublin, Dublin 8 Dublin, Ireland., Lacal JC; Grupo de Oncología Traslacional, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain.; Instituto de Investigaciones Biomédicas (IIB), CSIC, 28029 Madrid, Spain., Del Pozo A; Nanomedicine and Molecular Imaging group, Trinity Translational Medicine Institute (TTMI), Trinity College Dublin (TCD), Dublin 8 Dublin, Ireland., Pankhurst QA; Resonant Circuits Limited, London W1S 4BS, U.K.; Healthcare Biomagnetics Laboratory, University College London, London W1S 4BS, U.K., Hidalgo M; Grupo de Oncología Traslacional, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain., Gazeau F; Laboratoire Matière et Systèmes Complexes (MSC), UMR 7057 CNRS, Université Paris Diderot, Paris 75205, cedex, France., Somoza Á; IMDEA Nanociencia, Unidad Asociada al Centro Nacional de Biotecnología (CSIC) 28049 Madrid, Spain.; Unidad Asociada de Nanobiotecnología (CNB-CSIC e IMDEA Nanociencia), 28049 Madrid, Spain., Schwartz S Jr; Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT), Vall d'Hebron Institute of Research (VHIR), 08035 Barcelona, Spain.; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 08035 Barcelona, Spain.; Servei de Bioquímica, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain., Abasolo I; Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT), Vall d'Hebron Institute of Research (VHIR), 08035 Barcelona, Spain.; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 08035 Barcelona, Spain.; Functional Validation & Preclinical Research (FVPR), Unit20 ICTS Nanbiosis, Vall d'Hebron Institute of Research (VHIR), 08035 Barcelona, Spain.; Servei de Bioquímica, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain.; Instituto de Química Avanzada de Cataluña (IQAC), CSIC, 08034 Barcelona, Spain.
Jazyk:	angličtina
Zdroj:	ACS applied materials & interfaces [ACS Appl Mater Interfaces] 2025 Jan 02. Date of Electronic Publication: 2025 Jan 02.
DOI:	10.1021/acsami.4c16129
Abstrakt:	Pancreatic ductal adenocarcinoma (PDAC) is a very challenging disease with a very poor prognosis. It is characterized by a dense desmoplastic stroma that hampers drug penetration and limits the effectiveness of conventional chemotherapy (CT). As an alternative, the combination of CT with hyperthermia (HT) has been proposed as an innovative treatment modality for PDAC. In previous works, we reported on the development of iron oxide magnetic nanoparticles (MNPs) that, when exposed to time-varying magnetic fields, exhibit strong HT responses that inhibited the growth of pancreatic cancers. We report here on advances toward the clinical use of these MNPs as an intratumorally administered sterile magnetic fluid (the "NoCanTher ThermoTherapy" or "NTT" Agent) alongside intravenous standard-of-care drugs (gemcitabine and nab-paclitaxel) for the treatment of PDAC. In vitro cell viability assays show that the combination of low doses of CT and HT is highly synergistic, particularly in the BxPC-3 cell line. In vivo , biodistribution assays showed that the NTT Agent MNPs remained mainly within the tumor, concentrated around areas with a high stromal component. Moreover, the combined CT/HT treatment shows clear advantages over CT alone in terms of drug penetration and reduction of the tumor volume, suggesting a potential direct effect of HT in the disruption of the interstitial stroma to facilitate the access of the drugs to malignant cells. These studies have led to the approval and commencement of a clinical investigational study at the Vall d'Hebron University Hospital (Barcelona, Spain) of the NTT Agent alongside CT in patients with locally advanced PDAC.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu